临床儿科杂志 ›› 2022, Vol. 40 ›› Issue (2): 81-86.doi: 10.12372/jcp.2022.21e1625
• 专家笔谈 • 下一篇
张爱军, 刘芹芹, 浦婷
收稿日期:
2021-11-22
出版日期:
2022-02-15
发布日期:
2022-02-11
作者简介:
张爱军(1978—),女,青年编委,山东大学齐鲁医院儿科副主任,主任医师,医学博士,免疫学博士后,硕士研究生导师ORCID:0000-0002-6117-4560,哈佛大学高级访问学者。兼任中华医学会儿科学分会青年委员,中华医学会儿科学分会血液学组青年委员,中华医学会儿科分会互联网+专业委员会青年委员,中国研究型医院学会儿科学专业委员会青年委员,山东省儿科分会青年委员会副主任委员,山东省抗癌协会小儿肿瘤分会常务委员,山东省免疫学会青年委员。主持国家自然科学基金1项,省部级课题5项,发表SCI论文20余篇。
基金资助:
ZHANG Aijun, LIU Qinqin, PU Ting
Received:
2021-11-22
Published:
2022-02-15
Online:
2022-02-11
摘要:
免疫性血小板减少症(ITP)是儿童时期最为常见的出血性疾病,由多种自身免疫机制介导,以孤立性血小板减少为主要临床特点。儿童ITP通常急性起病,相当比例的患儿可追溯到前驱感染或接种疫苗史,均可使其免疫失耐受,从而导致ITP的发生。儿童ITP异质性较强,目前越来越多的患儿病情反复,一线治疗效果不佳,迁延不愈,导致慢性ITP增加,临床医师应根据每例患儿特点作出相应的个体化治疗,给予合理规范的疾病管理,综合评估治疗效果,减少治疗相关并发症,提高患儿生活质量。
张爱军, 刘芹芹, 浦婷. 儿童免疫性血小板减少症的规范治疗与管理[J]. 临床儿科杂志, 2022, 40(2): 81-86.
ZHANG Aijun, LIU Qinqin, PU Ting. Standardized treatment and management of immune thrombocytopenia in children[J]. Journal of Clinical Pediatrics, 2022, 40(2): 81-86.
[1] | 梅恒, 胡豫. 成人原发免疫性血小板减少症诊断与治疗中国指南(2020年版)解读[J]. 临床内科杂志, 2021, 38(6):431-432. |
[2] |
Rodeghiero F, Stasi R, Gernsheimer T, et al. Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group[J]. Blood, 2009, 113(11):2386-2393.
doi: 10.1182/blood-2008-07-162503 pmid: 19005182 |
[3] |
Cines DB, Bussel JB, Liebman HA, et al. The ITP syndrome: pathogenic and clinical diversity[J]. Blood, 2009, 113(26):6511-6521.
doi: 10.1182/blood-2009-01-129155 |
[4] |
Cecinati V, Principi N, Brescia L, et al. Vaccine admini-stration and the development of immune thrombo-cytopenic purpura in children[J]. Hum Vaccin Immunother, 2013, 9(5):1158-1162.
doi: 10.4161/hv.23601 |
[5] |
Audia S, Mahévas M, Samson M, et al. Pathogenesis of immune thrombocytopenia[J]. Autoimmun Rev, 2017, 16(6):620-632.
doi: 10.1016/j.autrev.2017.04.012 |
[6] |
Perdicchio M, Ilarregui JM, Verstege MI, et al. Sialic acid-modified antigens impose tolerance via inhibition of T-cell proliferation and de novo induction of regulatory T cells[J]. Proc Natl Acad Sci U S A, 2016, 113(12):3329-3334.
doi: 10.1073/pnas.1507706113 pmid: 26941238 |
[7] |
Li J, van der Wal DE, Zhu G, et al. Desialylation is a mechanism of Fc-independent platelet clearance and a therapeutic target in immune thrombocytopenia[J]. Nat Commun, 2015, 6:7737.
doi: 10.1038/ncomms8737 |
[8] |
Zhao HY, Ma YH, Li DQ, et al. Low-dose chidamide restores immune tolerance in ITP in mice and humans[J]. Blood, 2019, 133(7):730-742.
doi: 10.1182/blood-2018-05-847624 |
[9] |
Ikuse T, Toda M, Kashiwagi K, et al. Efficacy of eradication therapy on platelet recovery in pediatric immune thrombocytopenic purpura-case series and a systematic review[J]. Microorganisms, 2020, 8(10):1457.
doi: 10.3390/microorganisms8101457 |
[10] | 中国儿童原发性免疫性血小板减少症诊断与治疗指南改编工作组, 中华医学会儿科学分会血液学组, 中华儿科杂志编辑委员会. 中国儿童原发性免疫性血小板减少症诊断与治疗改编指南(2021版)[J]. 中华儿科杂志, 2021, 59(10):810-819. |
[11] |
Neunert C, Lim W, Crowther M, et al. The American Society of Hematology 2011 evidence-based practice guideline for immune thrombocytopenia[J]. Blood, 2011, 117(16):4190-4207.
doi: 10.1182/blood-2010-08-302984 pmid: 21325604 |
[12] | 侯明, 胡豫. 成人原发免疫性血小板减少症诊断与治疗中国指南(2020年版)[J]. 中华血液学杂志, 2020, 41(8):617-623. |
[13] |
Wei Y, Ji XB, Wang YW, et al. High-dose dexamethasone vs prednisone for treatment of adult immune throm-bocytopenia: a prospective multicenter randomized trial[J]. Blood, 2016, 127(3):296-302.
doi: 10.1182/blood-2015-07-659656 pmid: 26480931 |
[14] |
Sadeghi A, Hosseini SF, Jouzdani SR. Evaluation of treatment plan by three-period pulses of high-dose dexamethasone among patients with primary immune thrombocytopenia on platelet count response and adverse events: a randomized clinical trial[J]. J Res Med Sci, 2020, 25:88.
doi: 10.4103/jrms.JRMS_257_19 |
[15] |
Ma J, Fu L, Chen Z, et al. High-dose dexamethasone as a replacement for traditional prednisone as the first-line treatment in children with previously untreated primary immune thrombocytopenia: a prospective, randomized single-center study[J]. Int J Hematol, 2020, 112(6):773-779.
doi: 10.1007/s12185-020-02977-9 |
[16] |
Yu Y, Wang M, Hou Y, et al. High-dose dexamethasone plus recombinant human thrombopoietin vs high-dose dexamethasone alone as frontline treatment for newly diagnosed adult primary immune thrombocytopenia: A prospective, multicenter, randomized trial[J]. Am J Hematol, 2020, 95(12):1542-1552.
doi: 10.1002/ajh.v95.12 |
[17] | Wang J, Li Y, Wang C, et al. Efficacy and safety of the combination treatment of rituximab and dexamethasone for adults with primary immune thrombocytopenia (ITP): a meta-analysis[J]. Biomed Res Int, 2018: 1316096. |
[18] |
Feng Q, Xu M, Yu YY, et al. High-dose dexamethasone or all-trans-retinoic acid restores the balance of macrophages towards M2 in immune thrombocytopenia[J]. J Thromb Haemost, 2017, 15(9):1845-1858.
doi: 10.1111/jth.13767 pmid: 28682499 |
[19] | Grace RF, Shimano KA, Bhat R, et al. Second-line treatments in children with immune thrombocytopenia: effect on platelet count and patient-centered outcomes[J]. Am J Hematol, 2019, 94(7):741-750. |
[20] |
Zhou H, Xu M, Qin P, et al. A multicenter randomized open-label study of rituximab plus rhTPO vs rituximab in corticosteroid-resistant or relapsed ITP[J]. Blood, 2015, 125(10):1541-1547.
doi: 10.1182/blood-2014-06-581868 pmid: 25575541 |
[21] |
Chaturvedi S, Arnold DM, McCrae KR. Splenectomy for immune thrombocytopenia: down but not out[J]. Blood, 2018, 131(11):1172-1182.
doi: 10.1182/blood-2017-09-742353 pmid: 29295846 |
[22] |
Rodeghiero F. A critical appraisal of the evidence for the role of splenectomy in adults and children with ITP[J]. Br J Haematol, 2018, 181(2):183-195.
doi: 10.1111/bjh.2018.181.issue-2 |
[23] |
Álvarez-Román MT, Rivas Pollmar MI, Bernardino JI, et al. Thrombopoietin receptor agonists in conjunction with oseltamivir for immune thrombocytopenia[J]. AIDS, 2016, 30(7):1141-1142.
doi: 10.1097/QAD.0000000000001036 pmid: 27028144 |
[24] |
Shao L, Wu Y, Zhou H, et al. Successful treatment with oseltamivir phosphate in a patient with chronic immune thrombocytopenia positive for anti-GPIb/IX autoantibody[J]. Platelets, 2015, 26(5):495-497.
doi: 10.3109/09537104.2014.948838 |
[25] |
Revilla N, Corral J, Miñano A, et al. Multirefractory primary immune thrombocytopenia; targeting the decreased sialic acid content[J]. Platelets, 2019, 30(6):743-751.
doi: 10.1080/09537104.2018.1513476 pmid: 30296193 |
[26] |
Alioglu B, Tasar A, Ozen C, et al. An experience of oseltamivir phosphate (tamiflu™) in a pediatric patient with chronic idiopathic thrombocytopenic purpura: a case report[J]. Pathophysiol Haemost Thromb, 2010, 37(2-4):55-58.
doi: 10.1159/000321379 |
[27] |
de Vos D, van Overveld W. Decitabine: a historical review of the development of an epigenetic drug[J]. Ann Hematol, 2005, 84(Suppl 1):3-8.
doi: 10.1007/s00277-005-0008-x |
[28] | Han P, Hou Y, Zhao Y, et al. Low-dose decitabine modulates T-cell homeostasis and restores immune tolerance in immune thrombocytopenia[J]. Blood, 2021, 138(8):674-688. |
[29] |
Zhou H, Qin P, Liu Q, et al. A prospective, multicenter study of low dose decitabine in adult patients with refractory immune thrombocytopenia[J]. Am J Hematol, 2019, 94(12):1374-1381.
doi: 10.1002/ajh.25646 pmid: 31591739 |
[30] | Despotovic JM, Grimes AB. Pediatric ITP: is it different from adult ITP?[J]. Hematol Am Soc Hematol Educ Program, 2018, 2018(1):405-411. |
[31] |
Khelif A, Saleh MN, Salama A, et al. Changes in health-related quality of life with long-term eltrombopag treatment in adults with persistent/chronic immune thrombocytopenia: findings from the EXTEND study[J]. Am J Hematol, 2019, 94(2):200-208.
doi: 10.1002/ajh.v94.2 |
[32] |
Bennett CM, Neunert C, Grace RF, et al. Predictors of remission in children with newly diagnosed immune thrombocytopenia: Data from the Intercontinental Cooperative ITP Study Group Registry II participants[J]. Pediatr Blood Cancer, 2018, 65(1). doi: 10.1002/pbc.26736.
doi: 10.1002/pbc.26736 |
[33] |
Heitink-Pollé KMJ, Nijsten J, Boonacker CWB, et al. Clinical and laboratory predictors of chronic immune thrombocytopenia in children: a systematic review and meta-analysis[J]. Blood, 2014, 124(22):3295-3307.
doi: 10.1182/blood-2014-04-570127 pmid: 25305206 |
[34] |
Schmidt DE, Wendtland Edslev P, Heitink-Pollé KMJ, et al. A clinical prediction score for transient versus persistent childhood immune thrombocytopenia[J]. J Thromb Haemost, 2021, 19(1):121-130.
doi: 10.1111/jth.15125 pmid: 33058474 |
[35] |
Adly AAM, Ragab IA, Ismail EAR, et al. Evaluation of the immature platelet fraction in the diagnosis and prognosis of childhood immune thrombocytopenia[J]. Platelets, 2015, 26(7):645-650.
doi: 10.3109/09537104.2014.969220 |
[36] | 王丽媛, 刘亢亢, 储金华, 等. 儿童免疫性血小板减少症病程慢性化影响因素的研究[J]. 中国实验血液学杂志, 2021, 29(3):881-886. |
[37] |
Levy-Mendelovich S, Aviner S, Sharon N, et al. Pediatric immune thrombocytopenia: apoptotic markers may help in predicting the disease course[J]. Pediatr Res, 2021, 90(1):93-98.
doi: 10.1038/s41390-020-01355-9 pmid: 33504961 |
[38] |
Gu H, Chen Z, Shi X, et al. Increased proportion of Th17/Treg cells at the new diagnosed stage of chronic immune thrombocytopenia in pediatrics: the pilot study from a multi-center[J]. Eur J Pediatr, 2021, 180(11):3411-3417.
doi: 10.1007/s00431-021-04121-z |
[39] |
Vrbensky JR, Nazy I, Toltl LJ, et al. Megakaryocyte apoptosis in immune thrombocytopenia[J]. Platelets, 2018, 29(7):729-732.
doi: 10.1080/09537104.2018.1475637 pmid: 29787328 |
[40] |
Iraqi M, Perdomo J, Yan F, et al. Immune thrombocytopenia: antiplatelet autoantibodies inhibit proplatelet formation by megakaryocytes and impair platelet production in vitro[J]. Haematologica, 2015, 100(5):623-632.
doi: 10.3324/haematol.2014.115634 pmid: 25682608 |
[1] | 罗明静, 余嘉明, 王晓东, 张小玲, 余阅, 张瑜, 文飞球, 刘四喜. 424例地中海贫血患儿异基因造血干细胞移植后继发侵袭性真菌病临床分析[J]. 临床儿科杂志, 2025, 43(1): 21-28. |
[2] | 刘冬霞, 金蓉, 林荣军. 儿童重症难治性肺炎支原体肺炎并发闭塞性支气管炎危险因素分析[J]. 临床儿科杂志, 2025, 43(1): 29-34. |
[3] | 钟瑾虹, 王灿, 陈芳. 婴幼儿纤维支气管镜诊疗中镇静技术的研究进展[J]. 临床儿科杂志, 2025, 43(1): 50-55. |
[4] | 蒋卫芹, 王静, 程安娜, 陈婷婷, 黄玉娟. 儿童热性惊厥急性期惊厥复发的危险因素分析[J]. 临床儿科杂志, 2025, 43(1): 8-13. |
[5] | 邱琇, 韦冬梅, 林珊珊, 夏慧敏, 周文浩. 广州出生队列研究的理念与实践[J]. 临床儿科杂志, 2024, 42(9): 747-752. |
[6] | 陈倩, 田英, 孙锟, 张军. 关注环境、立足疾病的大型出生队列研究平台[J]. 临床儿科杂志, 2024, 42(9): 753-757. |
[7] | 范建霞. 健康生命轨迹计划缘起与发展:社区-家庭-母婴多层面儿童超重与肥胖干预研究队列[J]. 临床儿科杂志, 2024, 42(9): 768-773. |
[8] | 姜涛, 李双杰, 唐莲, 欧阳文献. 慢性乙型肝炎患儿外周血MAIT细胞的免疫生物学特性[J]. 临床儿科杂志, 2024, 42(9): 787-790. |
[9] | 周洁, 刘克强, 王金玲, 王莹. MYH11延长突变导致巨膀胱-小结肠-肠蠕动不良综合征1例报告及文献复习[J]. 临床儿科杂志, 2024, 42(9): 798-804. |
[10] | 褚思嘉, 汤继宏. 儿童急性淋巴细胞白血病及其治疗所伴发的中枢神经系统损伤研究进展[J]. 临床儿科杂志, 2024, 42(9): 811-816. |
[11] | 丁亚平, 夏姗姗, 张晨美. 《2023年国际儿童肾脏营养工作组临床实践建议:儿童急性肾损伤的营养管理》解读[J]. 临床儿科杂志, 2024, 42(8): 667-672. |
[12] | 李怡蓉, 李惠萍, 高靖瑜, 肖玉华, 陈小敏, 卢艳玲, 赵娜娜, 冯晓勤. FLAG-IDA诱导化疗方案中不同剂量阿糖胞苷治疗儿童急性髓系白血病疗效比较[J]. 临床儿科杂志, 2024, 42(8): 673-677. |
[13] | 黄博, 董艳迎, 宋琳岚. 儿童传染性单核细胞增多症348例临床特征分析[J]. 临床儿科杂志, 2024, 42(8): 678-683. |
[14] | 王丹, 邵静波, 李红, 张娜, 朱嘉莳, 付盼, 王真. 儿童血液系统恶性肿瘤并发肿瘤溶解综合征38例临床特点分析[J]. 临床儿科杂志, 2024, 42(8): 684-690. |
[15] | 马岩, 韦性娇, 白华, 张艳, 田新敏, Aqsa Ahmad, 梁丽俊. 西部地区某三甲医院儿童慢性肾脏病5期病因构成及临床特征分析[J]. 临床儿科杂志, 2024, 42(8): 697-703. |
Viewed | ||||||||||||||||||||||||||||||||||||||||||||||||||
Full text 2240
|
|
|||||||||||||||||||||||||||||||||||||||||||||||||
Abstract 1246
|
|
|||||||||||||||||||||||||||||||||||||||||||||||||
Cited |
|
|||||||||||||||||||||||||||||||||||||||||||||||||
Shared | ||||||||||||||||||||||||||||||||||||||||||||||||||
|